CagriSema vs Zepbound: Complete Comparison

CagriSema vs Zepbound: Complete Comparison

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice. Weight loss medications require a prescription and ongoing medical supervision. Discuss all treatment decisions with your healthcare provider, who can evaluate your individual health history, medications, and goals.

CagriSema did not beat Zepbound. That remains the single most important fact in this comparison, and the months since the REDEFINE-4 results have only strengthened Zepbound's position.

In the REDEFINE-4 head-to-head trial, CagriSema produced 22.2% weight loss compared to tirzepatide's 25.3%. CagriSema failed to prove non-inferiority — meaning it could not even demonstrate it was comparably effective, let alone superior. Tirzepatide, Zepbound's active ingredient, proved superior in the only direct comparison that exists between these two drugs.

Eighteen months after Novo Nordisk filed the CagriSema NDA, there is still no FDA decision and no publicly disclosed PDUFA date. Meanwhile, Zepbound is available today, established as the market leader for prescription weight loss, and competitively priced at roughly $299 per month through LillyDirect or as low as $25 per month with eligible commercial insurance. For most patients, the decision is straightforward: start treatment now with the medication that won the head-to-head trial.

This guide walks through the full comparison — mechanisms, trial data, side effects, cost, and availability — so you can have an informed conversation with your provider about what makes sense for your situation. For a deeper look at CagriSema alone, see our CagriSema patient guide. For Zepbound pricing details, see our Zepbound price guide.

What is the bottom line on CagriSema vs Zepbound?

Zepbound won the head-to-head REDEFINE-4 trial (25.3% vs 22.2% weight loss), is available now at ~$299/month cash pay, and has better tolerability. CagriSema has no approval date and is expected to cost more. For most patients asking "CagriSema vs Zepbound which is better," the evidence points clearly to Zepbound.

	CagriSema	Zepbound
Status	Not FDA approved (NDA filed Dec 2025, under review)	FDA approved and available — market leader
Head-to-head result	Lost to Zepbound in REDEFINE-4	Won the head-to-head comparison
Weight loss	22.2% (REDEFINE-4)	25.3% (REDEFINE-4)
Price	Projected $1,200-1,600/mo if approved	~$299/mo via LillyDirect; $25/mo with insurance
Recommendation	Wait unless you have a specific clinical reason	Start now for most patients

If you are currently deciding between waiting for CagriSema or starting Zepbound, the evidence strongly favors starting Zepbound. Every month you delay treatment is a month of continued obesity-related health risk without the metabolic benefits of pharmacotherapy. Zepbound is available, proven superior in the head-to-head trial, and more affordable than CagriSema is projected to be. You can always switch medications later if CagriSema offers specific advantages for your situation once it reaches the market.

Quick Comparison Table: CagriSema vs Zepbound

Factor	CagriSema (Novo Nordisk)	Zepbound (Eli Lilly)
Generic name	Cagrilintide + semaglutide	Tirzepatide
Mechanism	GLP-1 + amylin (dual pathway)	GLP-1 + GIP (dual agonist)
Key trial	REDEFINE program (1-4)	SURMOUNT program (1-4)
Weight loss (own trial)	22.7% at 68 weeks (REDEFINE-1)	22.5% at 72 weeks (SURMOUNT-1, 15mg)
Head-to-head weight loss	22.2% (REDEFINE-4)	25.3% (REDEFINE-4)
Non-inferiority	Failed vs tirzepatide	N/A (was the comparator)
Administration	Weekly subcutaneous injection	Weekly subcutaneous injection
FDA status	NDA filed Dec 2025; no PDUFA date disclosed	Approved November 2023
Availability	Not available	Available now
List price	Projected ~$1,200-1,600/mo	$1,059/mo list
Cash pay options	TBD	~$299/mo LillyDirect
Insurance	TBD	As low as $25/mo with eligible commercial insurance
Common side effects	Nausea, diarrhea, vomiting, injection site reactions	Nausea, diarrhea, decreased appetite
Notable safety signals	Increased heart rate	Gallbladder-related events

How do CagriSema and Zepbound work differently?

CagriSema combines semaglutide (GLP-1) with cagrilintide (amylin analog) — two drugs that suppress appetite through separate brain pathways. Zepbound is a single molecule that activates both GLP-1 and GIP receptors. The GIP activation is what likely explains Zepbound's edge in REDEFINE-4: it addresses both appetite and metabolic efficiency.

CagriSema and Zepbound both target multiple biological pathways to produce weight loss, but they do it through fundamentally different mechanisms. Understanding these differences helps explain why the clinical results diverged and which medication might suit your biology.

CagriSema: GLP-1 + Amylin

CagriSema combines two drugs in a single weekly injection:

Semaglutide 2.4mg is the same GLP-1 receptor agonist found in Wegovy and Ozempic. It suppresses appetite by acting on brain regions that control hunger and satiety, slows gastric emptying so you feel full longer, and improves blood sugar control. Semaglutide is the most extensively studied obesity drug in history, with cardiovascular outcome data from the SELECT trial demonstrating a 20% reduction in major cardiovascular events.

Cagrilintide 2.4mg is a long-acting analog of amylin, a hormone released by the pancreas alongside insulin after meals. Amylin suppresses appetite through brain pathways that are distinct from GLP-1 — specifically through the area postrema and the hypothalamus. The theory behind CagriSema is that stacking two appetite-suppression systems produces more weight loss than either alone.

The key limitation: both components work by reducing how much you eat. CagriSema does not meaningfully increase energy expenditure. All weight loss comes from the intake side of the energy balance equation.

Zepbound: GLP-1 + GIP Dual Agonist

Zepbound (tirzepatide) is a single molecule that activates two receptors simultaneously:

GLP-1 receptor activation provides the same appetite suppression, slowed gastric emptying, and blood sugar benefits that semaglutide delivers.

GIP (glucose-dependent insulinotropic polypeptide) receptor activation is what makes tirzepatide different from everything that came before it. GIP was originally considered an "obesity hormone" because higher GIP levels were observed in people with obesity. It seemed counterintuitive to activate this receptor for weight loss. But research showed that pharmacological GIP receptor agonism — at doses far higher than natural levels — reverses the effect. At therapeutic doses, GIP activation enhances insulin sensitivity, improves fat metabolism, and appears to reduce the metabolic adaptation that normally slows weight loss over time.

The GIP component may help explain why tirzepatide outperformed CagriSema in REDEFINE-4. Tirzepatide addresses both sides of the energy equation — reduced intake through appetite suppression and improved metabolic efficiency — while CagriSema focuses primarily on the intake side.

For a broader view of how these mechanisms compare to other emerging treatments, see our next-gen GLP-1 pipeline comparison.

What does the clinical trial data show for CagriSema vs Zepbound?

The most important data point is REDEFINE-4: in the same patients, tirzepatide produced 25.3% weight loss versus CagriSema's 22.2%, and CagriSema failed to prove non-inferiority. That 3.1 percentage point gap translates to roughly 8 additional pounds for a 250-pound patient.

The data from these trials should inform your decision, but context matters. Trial populations, endpoints, and timeframes differ between programs, which limits the precision of cross-trial comparisons. REDEFINE-4 is the exception — it directly compared the two drugs in the same patients.

REDEFINE-1: CagriSema's Flagship Result

• Population: Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, without type 2 diabetes
• Result: 22.7% mean weight loss at 68 weeks
• Comparator: Placebo (lost 2.1%)
• Key detail: Approximately 58% of CagriSema patients lost 20% or more of their body weight

This was a strong result against placebo and established CagriSema as a potent weight loss drug in absolute terms. But performance against placebo does not tell you how a drug compares to the current best option.

REDEFINE-2: CagriSema in Type 2 Diabetes

• Population: Adults with type 2 diabetes and obesity
• Result: 15.7% mean weight loss at 68 weeks
• HbA1c reduction: Significant (specific data varies by baseline)
• Context: Weight loss in T2D populations is consistently lower across all GLP-1 medications due to the metabolic effects of diabetes itself

REDEFINE-4: The Head-to-Head Trial That Defined the Comparison

This is the trial that matters most. REDEFINE-4 directly compared CagriSema to tirzepatide (the active ingredient in Zepbound) in the same patient population — and tirzepatide won.

• Population: Adults with obesity, without type 2 diabetes
• CagriSema result: 22.2% mean weight loss
• Tirzepatide result: 25.3% mean weight loss
• Primary endpoint: Non-inferiority of CagriSema vs tirzepatide
• Outcome: Non-inferiority was not met. CagriSema could not demonstrate it was even comparably effective to tirzepatide. Zepbound's active ingredient proved superior.

The 3.1 percentage point gap is clinically meaningful. For a person weighing 250 pounds, that is roughly 8 additional pounds lost on tirzepatide — a meaningful difference at the individual level. The failure to achieve non-inferiority means the confidence interval around that gap includes the possibility that the true difference is even larger.

This result was unexpected. Novo Nordisk had positioned CagriSema as the next step beyond semaglutide, and there was industry expectation that adding amylin to the best GLP-1 agonist would match or exceed tirzepatide's dual-agonist approach. The data showed otherwise, and it is one of the most consequential head-to-head results in the obesity pharmacotherapy space.

SURMOUNT-1: Tirzepatide's Landmark Trial

• Population: Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, without type 2 diabetes
• Result at 15mg dose: 22.5% mean weight loss at 72 weeks
• Result at 10mg dose: 21.4% mean weight loss at 72 weeks
• Result at 5mg dose: 16.0% mean weight loss at 72 weeks
• Key detail: Approximately 63% of patients on the 15mg dose lost 20% or more of their body weight

Cross-Trial Comparison Limitations

Comparing REDEFINE-1 (22.7%) to SURMOUNT-1 (22.5%) might suggest the drugs are similar. But that comparison has important limitations:

• Different trial populations, inclusion criteria, and demographics
• REDEFINE-1 measured at 68 weeks; SURMOUNT-1 at 72 weeks
• Different baseline weights and BMIs
• Different dietary and exercise counseling protocols

This is exactly why head-to-head trials like REDEFINE-4 exist. When you put both drugs in the same patients under the same conditions, tirzepatide won by a clear margin.

How do CagriSema and Zepbound compare on side effects?

Zepbound has lower GI side effect rates than CagriSema across every category — lower nausea (~25-30% vs 40-45%), lower discontinuation (4-7% vs 10-12%), and no injection site reactions. CagriSema's tolerability disadvantage is one of the strongest arguments for Zepbound.

Both medications carry gastrointestinal side effects as the primary tolerability concern. This is expected for any drug that works through GLP-1 receptor pathways. However, the profiles differ in important ways.

CagriSema Side Effects

Gastrointestinal effects remain the most common adverse events:

• Nausea: reported in approximately 40-45% of patients across REDEFINE trials
• Diarrhea: approximately 20-25%
• Vomiting: approximately 15-20%
• Constipation: approximately 12-15%

Injection site reactions are more frequent with CagriSema than with semaglutide or tirzepatide alone. The cagrilintide component appears to cause local reactions — redness, swelling, or itching at the injection site — in a higher proportion of patients. These reactions are generally mild and tend to decrease over time, but they represent an additional tolerability burden not seen with Zepbound.

Increased heart rate was identified as a signal across the REDEFINE program. Small increases in resting heart rate (approximately 3-4 beats per minute on average) were observed more frequently with CagriSema than with semaglutide alone. The clinical significance of this finding is debated, but it warrants monitoring, particularly in patients with pre-existing cardiac conditions.

Discontinuation due to side effects: Approximately 10-12% across REDEFINE trials.

Zepbound Side Effects

Gastrointestinal effects are the most common, but rates are notably lower than with semaglutide-based products:

• Nausea: approximately 25-30% (lower than semaglutide at equivalent efficacy)
• Diarrhea: approximately 17-20%
• Vomiting: approximately 10-12%
• Constipation: approximately 10-12%

Gallbladder-related events including cholecystitis and cholelithiasis (gallstones) have been reported at higher rates with tirzepatide than with placebo. This is a class effect seen with rapid weight loss from any GLP-1 medication, but the incidence appears slightly elevated with tirzepatide. Patients with a history of gallbladder disease should discuss this with their provider.

Decreased appetite is reported as an adverse event in roughly 20% of patients, though many consider this the intended effect rather than a side effect.

Discontinuation due to side effects: Approximately 4-7% across SURMOUNT trials — meaningfully lower than CagriSema's discontinuation rate.

The GI Tolerability Advantage

One of Zepbound's underappreciated advantages is its tolerability profile. Despite producing more weight loss than CagriSema in the head-to-head trial, Zepbound generally causes fewer and less severe GI side effects than semaglutide-based regimens. The GIP receptor activation appears to have a protective effect on gastric motility that partially offsets the GLP-1-driven slowing of gastric emptying.

This means Zepbound delivers more efficacy with better tolerability — a combination that strongly favors it for most patients. For a broader comparison of how these side effect profiles compare to semaglutide-only products, see our Zepbound vs Wegovy comparison.

How do CagriSema and Zepbound compare on cost and access?

Zepbound costs ~$299/month cash pay through LillyDirect or as low as $25/month with eligible commercial insurance. CagriSema has no pricing, no approval, and no availability. The projected $1,200-1,600/month estimate for CagriSema would make it four to five times more expensive than insured Zepbound — for a medication that lost the head-to-head trial.

Cost is often the deciding factor in medication choice. Here, Zepbound has a significant structural advantage: it is available, established, and competitively priced.

Zepbound Pricing (Available Now)

• List price: $1,059.87 per month
• LillyDirect (cash pay): ~$299 per month — no insurance required, shipped to your door
• Commercial insurance: As low as $25/month with eligible savings card
• Coverage: Most major commercial insurers now cover Zepbound for obesity. Check with your plan.

Eli Lilly has been aggressive on pricing, and the LillyDirect program has made Zepbound one of the most accessible branded GLP-1 medications on the market. For a full breakdown of pricing options by insurance status, see our Zepbound price guide.

CagriSema Pricing (Projected)

• Projected cost: $1,200-1,600 per month. As a Novo Nordisk combination product, analysts expect pricing at or above Wegovy's list price ($1,349/month), reflecting the dual-drug formulation.
• Cash pay programs: Not announced. Novo Nordisk has historically relied more heavily on insurance coverage and copay cards than on cash-pay models like LillyDirect.
• Insurance coverage: Unknown. New-to-market medications typically face 6-12 months of limited formulary placement as insurers evaluate them.
• Medicare: Coverage will depend on how CagriSema is classified and whether it receives specific obesity or diabetes indications.

The pricing gap is substantial. Even at the low end of projections, CagriSema would cost four to five times what insured patients pay for Zepbound. For cash-pay patients, CagriSema at $1,200-1,600 per month versus Zepbound at roughly $299 per month is a significant cost difference — especially for a medication that produced less weight loss in the head-to-head trial.

When will CagriSema be available compared to Zepbound?

Zepbound has been available since late 2023 with stable supply. CagriSema's NDA was filed in December 2025 with no PDUFA date disclosed — a decision is expected in Q1 2027 at the earliest, followed by another 3-6 months to broad availability.

Zepbound: Available Now

Zepbound has been on the market since late 2023. It is the established market leader for prescription weight loss, available through retail pharmacies, mail-order pharmacies, and Eli Lilly's direct-to-patient LillyDirect platform. Supply shortages that affected 2024 have fully resolved.

CagriSema: Not Available — No FDA Decision After 18 Months

• December 2025: Novo Nordisk filed the New Drug Application (NDA) with the FDA
• Expected timeline: As of April 2026, no PDUFA date has been disclosed. The FDA decision is expected in Q1 2027, approximately 10-15 months after the December 2025 NDA filing. with no FDA decision and no publicly disclosed PDUFA target action date
• Timeline uncertainty: The standard 10-month review window has long since elapsed. The reasons for the extended review have not been publicly disclosed. It could reflect additional data requests, manufacturing questions, or other regulatory considerations.
• If approved, 3-6 months to broad availability: Manufacturing scale-up, pharmacy distribution, formulary negotiations, and savings program launches all take time. Patients should expect limited availability in the first months after any approval.

For the latest updates on the approval timeline, see our CagriSema PDUFA decision guide.

What the delay means for patients: The extended review period adds uncertainty on top of uncertainty. CagriSema demonstrated clear superiority over placebo, so approval is plausible — but the timeline is unknown, and the REDEFINE-4 non-inferiority failure against tirzepatide could affect labeling, indication scope, or post-marketing requirements. The FDA may also have requested additional data or imposed requirements that are not yet public. Patients should not plan their treatment decisions around a specific CagriSema approval date.

How is the competitive landscape shifting around CagriSema and Zepbound?

The obesity treatment landscape is getting more crowded, not less — survodutide and retatrutide are both advancing, which further weakens the case for waiting on CagriSema when Zepbound already leads the head-to-head trial.

It is worth noting that CagriSema and Zepbound are not the only options in play. Survodutide, a dual GLP-1/glucagon receptor agonist from Boehringer Ingelheim, is emerging as another competitor in the obesity space. The weight loss landscape is becoming increasingly competitive, which further diminishes the strategic case for waiting on any single unapproved medication when effective, available options exist.

For a broader view of the pipeline, see our next-gen GLP-1 pipeline comparison.

Who might still prefer CagriSema over Zepbound?

The primary candidates: patients who cannot tolerate tirzepatide, patients already on semaglutide who want more efficacy without switching drug classes, and those who prioritize the semaglutide component's cardiovascular outcomes data from the SELECT trial.

Despite the REDEFINE-4 result and the prolonged approval timeline, there are specific clinical scenarios where CagriSema could make sense for individual patients. If CagriSema is eventually approved and becomes available, consider discussing it with your provider if:

You cannot tolerate tirzepatide. Some patients experience side effects on tirzepatide that are not manageable despite dose titration. Because CagriSema uses a completely different secondary pathway (amylin vs GIP), its side effect profile is distinct. A patient who does poorly on tirzepatide might tolerate CagriSema differently.

You are already on semaglutide and want more weight loss without switching drug classes. If you are on Wegovy or Ozempic and have plateaued, CagriSema adds the amylin component on top of the semaglutide you are already taking. This could allow a boost in efficacy without the disruption of switching to an entirely different medication class. Your provider can assess whether this makes clinical sense for your situation.

You have comorbidities where amylin pathway modulation may offer specific benefits. The dual mechanism of GLP-1 plus amylin may offer different metabolic benefits than GLP-1 plus GIP. Early data suggests that amylin analogs may have independent effects on gastric emptying, bone density preservation during weight loss, and post-meal glucose control that differ from GIP-based approaches. These potential benefits are not yet well-established in large trials, but they may matter for specific patient profiles.

You have cardiovascular risk factors and want to stay within the semaglutide ecosystem. Semaglutide has robust cardiovascular outcome data from the SELECT trial. Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is still ongoing. For patients where cardiovascular risk reduction is a primary treatment goal alongside weight loss, the semaglutide backbone in CagriSema may offer additional reassurance — though this is an area of active research.

For a look at how CagriSema compares to other pipeline drugs, see our CagriSema vs retatrutide comparison.

Who should choose Zepbound now instead of waiting for CagriSema?

Most patients. Zepbound won the head-to-head trial, is available today at competitive pricing, and has better tolerability. If you're asking "is CagriSema worth waiting for," the data says no for the typical patient — you can always switch later if CagriSema offers specific advantages.

For most patients considering obesity pharmacotherapy in early 2026, Zepbound is the stronger choice. The case has only grown clearer since our original comparison.

Superior head-to-head data. Zepbound won the only direct comparison trial. A 25.3% vs 22.2% result, with CagriSema failing non-inferiority, is a definitive clinical signal. Tirzepatide is the proven winner.

Available today, established supply. Zepbound has been on the market for over three years. Supply is stable, distribution is mature, and patients are not subject to the uncertainty of an unapproved drug with no timeline for FDA action.

Competitive pricing. At roughly $299 per month through LillyDirect or as low as $25 per month with eligible commercial insurance, Zepbound is among the most affordable branded GLP-1 medications. CagriSema is projected at $1,200-1,600 per month — four to five times the cost for a medication that produced less weight loss.

Better tolerability profile. Lower rates of GI side effects and lower treatment discontinuation rates mean you are more likely to stay on Zepbound long enough to see results.

You can always switch. Starting Zepbound now does not lock you in. If CagriSema is approved and offers specific advantages for your profile, your provider can transition you. Weight loss medications are not permanent commitments — they are tools your medical team adjusts over time.

How should you make your decision between CagriSema and Zepbound?

Start with what's available. Zepbound won the head-to-head trial, is accessible now, and is priced competitively. If CagriSema eventually offers specific advantages for your situation — tirzepatide intolerance, cardiovascular considerations, semaglutide ecosystem preference — your provider can make that transition.

The comparison between CagriSema and Zepbound has become even more straightforward since this guide was first published. Zepbound is currently available while CagriSema awaits an FDA decision expected in Q1 2027. Meanwhile, Zepbound's position has only strengthened — it remains the medication that won the head-to-head trial, is widely available, and is competitively priced.

For the majority of patients, the right move is to start Zepbound now — or whichever available GLP-1 medication your provider recommends based on your insurance, health history, and treatment goals.

If you have a specific clinical reason to wait for CagriSema — tirzepatide intolerance, cardiovascular considerations, or a desire to stay within the semaglutide ecosystem — discuss that reasoning explicitly with your prescriber. Make sure the potential benefit of waiting justifies the concrete cost of delaying treatment, especially when the approval timeline is unknown.

Weight loss pharmacotherapy is most effective when started early and maintained consistently. The best medication is the one you can access, afford, and tolerate today.

Frequently Asked Questions

Is CagriSema better than Zepbound for weight loss? No — not based on available data. In REDEFINE-4, Zepbound (tirzepatide) produced 25.3% weight loss compared to CagriSema's 22.2%. CagriSema failed to prove non-inferiority. Zepbound won the only head-to-head comparison between these medications.

Should I wait for CagriSema or start Zepbound now? Start Zepbound now. CagriSema did not beat tirzepatide in the clinical trial, its FDA approval timeline is uncertain (expected Q1 2027 at the earliest), and it will likely cost more. Every month without treatment is a month of continued metabolic risk. You can always switch medications later if CagriSema offers specific advantages once it reaches the market.

How much does Zepbound cost compared to CagriSema? Zepbound costs approximately $299/month through LillyDirect or as low as $25/month with eligible commercial insurance. CagriSema pricing has not been announced — analysts project $1,200-1,600/month based on Novo Nordisk's pricing history and the combination formulation.

Does CagriSema or Zepbound have better side effects? Zepbound has a meaningfully better tolerability profile. Nausea rates are roughly 25-30% with tirzepatide versus 40-45% with CagriSema. Discontinuation due to side effects is 4-7% for Zepbound versus 10-12% for CagriSema. CagriSema also causes injection site reactions that tirzepatide does not.

What is the main difference between CagriSema and Zepbound? CagriSema combines semaglutide (GLP-1) with cagrilintide (amylin analog) in a weekly injection. Zepbound is a single molecule that activates GLP-1 and GIP receptors simultaneously. Zepbound is FDA-approved and available; CagriSema is under FDA review with no confirmed timeline.

Is CagriSema worth it compared to Zepbound? For most patients, no — Zepbound is available, more effective in head-to-head data, better tolerated, and competitively priced. CagriSema may eventually be worth considering for specific clinical scenarios (tirzepatide intolerance, cardiovascular risk with semaglutide preference), but those are narrow exceptions, not the typical patient profile.

---

This comparison was last updated on April 2026. Clinical trial data is sourced from published results of the REDEFINE and SURMOUNT trial programs. Pricing reflects publicly available information from Eli Lilly and Novo Nordisk as of April 2026. We will update this page as the CagriSema regulatory process progresses. For ongoing updates, bookmark our CagriSema PDUFA decision guide.

Telehealth Ally does not accept payment from pharmaceutical companies and has no financial relationship with Novo Nordisk or Eli Lilly. Our comparisons are based on publicly available clinical and pricing data.